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Abstract
Although our understanding of dual diagnosis has improved in recent years, a deficit
exists in our knowledge of how schizophrenia spectrum disorders (SSD) manifest themselves in
individuals with intellectual disabilities (ID). We also know very little about the behavioral
problems present with the ID population based on the existence of psychopathology. The
present research attempted to extend the literature by comparing behavior problems of
individuals with intellectual disability with SSD, any form of psychopathology, and no
psychopathology.
Utilizing the Behavior Problems Inventory (BPI), three areas of problem behaviors were
examined (self-injurious behavior, stereotypic behavior, and aggressive/destructive behavior)
and a total behavior problem score was also assessed. Correlations between diagnostic criteria
from the Diagnostic Assessment for the Severely Handicapped-II (DASH-II) and problem
behaviors were also assessed to examine convergence between the diagnostic instrument and the
behavior problems related to associated disorders. Results indicated that the SSD group was
unique when compared to the control group for frequency and severity of stereotyped behaviors
as well as their overall behavior problem scores. Despite these findings, behavior problems
assessed were not unique to the SSD population; as the data suggests these behavioral
differences were due to any form of psychopathology. These results warrant further exploration.
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Introduction
The study of Schizophrenia Spectrum Disorders (SSD) in the Intellectually Disabled (ID)
population requires reviewing several key areas, as there has been limited research done
specifically on SSD within the ID population. SSD is a term used to identify a group of
disorders sharing clinical features with schizophrenia, which include many psychotic disorders.
The terminology and grouping of disorders has been utilized by researchers previously (Erkiran,
Özünalan, Evren, Aytaclar, Kirisci, & Tarter, in press; Esterberg & Compton, 2005; Lysaker,
Davis, & Lightfoot, 2005; Lysaker & Hammersley, in press; Margolese, Malchy, Negrete,
Tempier, & Gill, 2006; Matsura, Adachi, Oana, Okubu, Kato, Nakano, & Matsura, 2004;
Mizrahi, Kiang, Mamo, Arenovich, Bagby, Zipursky, & Kapur, 2006; Rodríguez-Sánchez,
Crespo-Facorro, Iglesias, Bosch, Álvarez, & Llorca, 2005; Roofeh, Cottone, Burdick, Lencz,
Gyato, & Cervellione, 2006; Sim, Mahendran, Siris, Heckers, & Chong, 2004; Ueland, Øie,
Landrø, & Rund, 2004). The term SSD has been used to identify disorders such as
schizophrenia, schizoaffective disorder, and psychotic disorder, NOS in nearly all
aforementioned studies. In addition delusional disorder and schizophreniform disorder were
included as qualifying disorders in a majority of others. Psychotic mood disorder was also
included sparingly as an SSD in the literature. Within the population studied, all but
schizophreniform disorder and psychotic mood disorder were included in the SSD population.
This literature review begins with an examination of general psychopathology in the ID
population followed by an examination of schizophrenia in the general population. In addition,
potential treatments for SSD will be reviewed. A review of schizophrenia in the ID population
will follow including a review of dual diagnosis. Finally, behavior problems in the ID
population will be discussed.
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Psychopathology in the Intellectually Disabled
Prevalence
The rate of psychopathology in persons with ID is generally considered to be higher than
for the general population (Nezu, Nezu, & Gill-Weiss, 1992; Reiss, 1990; Rojahn & Tassé,
1996). The majority of the researchers estimate psychopathology rates of the intellectually
disabled to be 4 to 5 times higher than those of normal intelligence across all forms of
psychopathology (Rutter, Tizard, & Yule, 1976; Singh, Sood, Soneklar, & Ellis, 1991). A
review completed by Reid (1989a) reported prevalence rates for psychiatric disorders in patients
with ID to vary from 37% to 58.8%, which included all age ranges within hospital, community,
and total population samples.
Psychotic disorders have been found to be more prevalent in individuals with ID (Došen
& Day, 2001). The psychotic disorders discussed coincide with disorders falling under the
definition of SSD within this review. Markedly lower (than generally accepted) prevalence rates
of schizophrenia in persons with ID were found in only one study, where an overall prevalence
rate of 1.3% was found. However, even in this sample, rates of 2.6% and 3.3% were found in
patients with mild to borderline ID (Lund, 1985). However, the Lund study was often criticized
for methodological flaws (Blazer, George, Landerman, Pennybacker, Melville, Woodbury, et al.,
1986; Robins, Helzer, Weissman, Orvaschel, Gruenberg, Burke, et al., 1984), including lack of
interviews for all participants included in the study. Although agreement on actual prevalence
rates of psychopathology in the ID population may vary, it is generally accepted that rates are
higher than the general population.
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Schizophrenia
History
The person most often credited with identifying the disorder we call schizophrenia today
is Emil Kraepelin. However, the term Kraepelin used to label this phenomenon was “dementia
praecox”. After studying a large cohort of severely mentally ill patients over several decades, he
was the first to differentiate mood-related psychotic disorders from those with dementia praecox
(Kraepelin & Gosline, 1919). This distinction has continued in nearly every classification
system since its description (Flaum, 1995).
The term schizophrenia was first proposed by Eugen Bleuler. Bleuler focused on
characteristic and fundamental sets of symptoms that were observable during the course of
illness. Diagnostically, these symptoms were referred to as the “four A’s”; affective flattening,
associative loosening, ambivalence, and autism (Flaum, 1995). Affective flattening was
considered a marked diminution in emotional expressiveness. Associative loosening consisted of
disorganization in thought process. Ambivalence was considered as the inability to initiate and
follow through on simple tasks. Autism was involving one’s profound degree of social and
interpersonal relatedness. Although the terminology has been modified over the years, the
symptoms have remained relatively stable.
In Europe, Kurt Schneider was researching the same illness around the same time as
Bleuler. His methodology of focusing on cross-sectional observation rather than longitudinal
course was otherwise similar to Bleuler. The term Schneiderian symptoms of schizophrenia was
used to identify many of these positive symptoms of the disorder. However, his work did not
enjoy the long-term success of Kraepelin and Bleuler, as subsequent studies did not support his
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findings (Andreasen & Akiskal, 1983; Carpenter, Strauss, Muleh, 1973; Flaum & Andreasen,
1991; Silverstein & Harrow, 1981).
Primarily, Schneider focused on what are considered negative symptoms rather than the
positive symptoms in today’s classification system examined by Bleuler. Among his
contributions to the field of schizophrenia, his influence in broadening Kraepelin’s concept of
dementia praecox to include more mild and nonpsychotic forms of illness were most notable
(Flaum, 1995).
Accepted definitions and classifications of schizophrenia have evolved greatly over the
years. Our understanding of schizophrenia has developed from specific dimensions of what
constitutes schizophrenia and, more specifically, under which dimension specific symptoms are
grouped. At one time, a single common process was believed to underlie schizophrenic
symptoms and premorbid social adjustment (Andreasen & Olsen, 1982). However, more
complicated models have evolved over time.
Generally accepted models have ranged from two to four factors. An early two-factor
model was proposed by Lenzenweger, Dworkin, & Wethington (1989). This model will be
discussed in greater detail later in this section. An even earlier model of Schizophrenia proposed
three factors. This three-factor model proposed by Strauss, Carpenter, & Bartko (1974) was
markedly ahead of other researchers; as it was supported by later research (Crow, 1987;
Lenzenweger, Dworkin, & Wethington, 1991). This three-factor model described positive
symptoms, negative symptoms, and premorbid social adjustment as being independent and
distinguishable from one another. However, this research did not get the same attention in the
field as did work by other researchers.
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Other three-factor models evolved and had more success. One of the larger steps forward
in our understanding of schizophrenia came when Liddle (1987) partitioned the positive
symptoms into two separate dimensions; ‘reality distortions’ such as hallucinations and delusions
and ‘disorganizations’ such as tangentiality, derailment, and bizarre behaviors. Similar
suggestions regarding the dimensions of schizophrenia were supported by Bilder, Mukherjee, &
Rieder (1985), although both samples used were relatively small, limiting generalizability.
The first four-factor model was established by Liddle (1991). This fourth factor was
derived essentially by dividing the positive symptoms into reality distortion (e.g., delusions and
hallucinations) and disorganizations, (e.g., thought disorder and bizarre behaviors). Further
support for a four-factor model came with Lenzenweger & Dworkin, 1996. This study will also
be discussed in greater detail later in this section.
One of the more influential studies on schizophrenia was the previously mentioned work
by Lenzenweger et al., (1989). Using exploratory factor analysis (EFA), they attempted to
determine if they could account for the organization of phenotypic schizophrenic symptomology
identified in prior studies. This study first suggested their original two-factor model of
schizophrenia consisting of positive symptoms and negative symptoms, with the negative
symptoms loading disordered premorbid personal and social relations. Over time, this theory has
been revised and the factors of schizophrenia have been adjusted. The two factor model was
quickly replaced with a three-factor model (Lenzenweger, et al, 1991). However, a fourth factor
began to emerge from some of the same researchers within a few years.
Lenzenweger et al. (1996) examined case histories of 192 individuals, a considerably
larger sample size than previously employed. These researchers identified four underlying
dimensions of schizophrenia phenomenology instead of the previously accepted three
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(Lenzenweger et al., 1991). The four factors the authors identified which best accounted for
schizophrenia phenomenology were negative symptoms, disordered premorbid personal-social
relations, reality distortion, and disorganization. The 1996 study used a more stringent process
of confirmatory factor analysis (CFA) for statistical analysis instead of EFA. Four factors appear
relatively independent of one another, lending further support to the four factor model being
superior to the three factor model. This model continues to have support in the literature
regarding our understanding of schizophrenia.
However, the belief in dimensions/factors of schizophrenia for diagnostic purposes is not
universal. Others have considered using categorical criteria instead of dimensions. A study
involving 980 participants from the Australian National Survey of Mental Health focused on this
issue. Measures of psychopathology using factors explained more of the variance in areas of
service demand, dysfunctional behavior, social adaptation, global occupation, and function
(Rosenman, Korten, & Medway, 2003). Categorical criteria used in grouping behaviors as
opposed to the previously discussed factor structure have also been used. These categorical
criteria were only able to better predict the use of support services and course of illness, which
may be far more useful in areas of public health administration and budgeting as compared to the
area of diagnostic ability Psychologists generally focus their efforts (Rosenman et al., 2003).
Mental health professionals have also focused on the impact of schizophrenia on other
aspects of patients’ lives. Patients suffering from SSD also abuse drugs and alcohol at higher
rates than the general population (Margolese, Malchy, Negrete, Tempier, & Gill, 2004). These
associations are more applicable in the realm of those with mild or moderate ID who live in
community settings than for the institutionalized, but still warrants mention in terms of treatment
outcomes focusing on more independent living. Substance abuse was studied in over 200
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outpatients suffering from schizophrenia and related psychoses in a continuing care facility in
Canada. The three most commonly abused substances were nicotine, alcohol, and cannabis.
Based on their psychiatric diagnoses and substance abuse backgrounds, patients were grouped by
those with just a mental disorder or a mental disorder with an additional addictive disorder. For
alcohol and cannabis, 44.9% of the sample met criteria for lifetime abuse/dependence and 14.0%
met criteria for current abuse/dependence. Current substance abuse/dependence and a psychotic
disorder was linked to higher Positive and Negative Symptom Scales positive scores than those
with a single diagnosis or a lifetime dual diagnosis. Individuals with SSD and a substance abuse
problem also were more likely to be non-compliant with medication than those with a single
diagnosis. In addition, Margolese et al. (2004) found those with SSD and substance abuse
problems were far more likely to smoke cigarettes than those with a single diagnosis (88.9%
compared to 49.6%) and had smoked longer (19.1 compared to 11.5 years).
Social functioning is also affected by SSD. Problems with social functioning have been a
noted characteristic of schizophrenia (Bellack, 1986). Further support for the inability of those
with schizophrenia to normally function in society was found in Smith, Shah, Wright & Lewis
(1995). In an analysis of the costs of psychiatric disorders, schizophrenia was found to account
for the second-highest burden on National Health Services (behind learning disability). In
addition, schizophrenia accounted for one-third of inpatient bed occupancies. These results
highlight the importance of the disorder, even though its prevalence rate is significantly lower
than many other disorders. A slight improvement in how we treat and care for individuals with
schizophrenia has the potential to incredibly reduce the burden on the mental health system.

7

Diagnostic Criteria
In The Diagnostic and Statistical Manual of Mental Disorders, IV-TR (DSM-IV-TR)
(American Psychological Association, APA, 2000) schizophrenia is defined as a disorder that
lasts for at least six months and includes at least one month (or less if successfully treated) of
active-phase symptoms of two or more of the following active symptoms over a one month
period of time: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic
behavior, negative symptoms. Only one of these criterion is required if delusions are bizarre or
hallucinations consist of a voice keeping running commentary of a person’s behavior or
thoughts, or two or more voices conversing with one another (pp. 298-302).
Social or occupational dysfunction occurring for a significant portion of the time since
the onset of symptoms in one or more of the following major areas of functioning is also
required: work, interpersonal relations, or self-care being markedly below where it was prior to
the onset of symptoms. During those months the active symptoms are not dominant, individuals
may suffer from “primarily negative symptoms or more mild forms” of the earlier mentioned
positive symptoms; this is often referred to as the residual period. Next, Schizoaffective
Disorder and Mood Disorder with Psychotic Features need to be ruled out based on the absence
of Major Depressive, Manic, or Mixed Episodes occurring concurrently with the active-phase
symptoms or the mood episodes occurring during active-phase symptoms must have been of
brief total duration when compared to the active and residual periods of symptoms. Ruling out
the possibility that symptoms are a result of a substance or general medical condition is also
important. A special consideration for Pervasive Developmental Disorders also exists. If a
diagnosis of Autistic Disorder or Pervasive Developmental Disorder exists, the additional
diagnosis of Schizophrenia can be made “only in the presence of prominent delusions or
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hallucinations for at least a month, unless symptoms are successfully treated” (p. 299) (American
Psychological Association, APA, 2000).
The difficulties which arise in diagnosing schizophrenia within certain populations
(individuals with severe and profound ID, for example) are immediately apparent based on this
definition; this issue will be more thoroughly reviewed in the Schizophrenia in the Intellectually
Disabled section. In addition, mixed mood states with features of mania, depression,
schizoaffective psychoses, psychotic responses to acute stress, and rapid-cycling bipolar disorder
all have been reported to be more common in the mentally retarded population than the general
population (Day, 1990; Glue, 1989; Reid, 1972; Sovner & Pary, 1993).
Beyond the identification of schizophrenia, it is imperative to look at how the mental
health system currently handles clients with schizophrenia. This is accomplished by looking at
where the mental health system is at, where it needs to move in the future, and finally by
examining what treatments are available today.
Treatment and Care for Schizophrenia Spectrum Disorders
Needs
Today’s mental health system often operates in a state where funding availability only
allows for minimal services to individuals from staff whose number and expertise levels are
often limited by these financial constraints. Within the realm of ID, mental health professionals
largely agree the availability and adequacy of therapeutic and other support services is poor
(Jacobson & Ackerman, 1988). Without adequate assessment, the treatment these individuals
receive may be inappropriate and/or ineffective. In order to monitor treatment effectiveness,
there must be a link between assessment and treatment in order to ensure therapeutic changes
occur. Unfortunately, most of the empirically supported research on SSD has centered on areas
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that are not cost effective or easily implemented; often requiring the use of well-trained staff
(Clark, 2001). Research ought to focus on assessments and treatments which are efficient and
simple enough for staff with limited training to be able to participate in treatment (Matson,
Kuhn, & Mayville, 2002). The limited resources available for mental health care today place
demands on mental health professionals requiring such efficiency while remaining practical and
applicable in the field.
Review of Treatments
In a review of pharmacological treatment studies of those with ID and schizophrenia,
Duggan and Brylewski (1999) concluded that many studies could not be included in their review
due to lack of randomization or placebo control. Inclusion criteria for this review included both
participants with ID, schizophrenia, and both ID and schizophrenia. Many studies also lacked
participants with ID and SSD diagnoses, so they could not be used for comparison reasons in this
study. Ultimately, only one study fit their inclusion criteria (Foote, 1958). Unfortunately, with
only one study meeting their inclusion criteria, the study was unable to contribute as much to the
literature as the authors initially hoped. The authors cited the lack of included studies to be “a
reflection of a genuine dearth of usable material” (p.102) and not strict inclusion criteria for their
study. More research needs to be completed to better understand how this disorder affects
individuals with ID.
Recent breakthroughs in psychopharmacology have increased the ability of the mental
health profession to improve treatment of psychopathology in both the normal and ID
population. However, the limited verbal communication skills often associated with varying
levels of ID seriously limit the effectiveness of client-patient dialogue (Sovner, 1986) and selfreport data (Reiss, 1994) which are important in treatment planning. Shortcomings in feedback
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from patients hamper the ability to tailor treatment plans in a way to improve the quality of life
for individuals with ID, such as less restrictive living situations.
Antipsychotic drugs have improved the lives of many with schizophrenia since their
introduction in the 1950s (Briggs, 1989; Clarke, 2001; Ereshefsky, Wantabe, & Tran-Johnson,
1989; Liberman, 2005). Chlorpromazine and other neuroleptic drugs have had success in
reducing positive symptoms such as delusions and hallucinations, but have little ability to reduce
negative symptoms (Clarke, 2001). These drugs may act to improve a person’s ability to
function outside of an institutional setting, but still leave much to be desired in terms of
rehabilitation outcomes. The efficacy of these medications within the ID population appears to
be similar to the general population; although fewer studies have been conducted with these
individuals.
Maintenance of treatment also appears to affect outcomes. Following the treatment of
acute symptoms, it appears that outcomes are better if maintenance doses of antipsychotic
treatments are given for one year (Johnson, 1979). With maintenance treatments, approximately
33% of patients remain relapse-free within a 2-year period compared to 20% without. Within 5
years, about 80% of patients relapsed after medication was discontinued (Johnson, Pasterski, &
Ludrow, 1983). Problems with adverse effects of medications have led to the best practice of
maintaining patients on the minimum number of medications at the minimum effective dosages.
Briggs (1989) found the use of monitoring systems such as interdisciplinary teams and
behavioral intervention committees have allowed the use and maintenance of psychotropic drug
use to drop to 20% of what it was without such committees within institutionalized settings.
These results highlight the relative lack of long term treatment effectiveness. Due to the chronic
nature of the disorder, lifelong treatment is a realistic expectation; improving our abilities to treat
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these disorders would be of great benefit. The following review of available medications will
evaluate some of the most commonly prescribed medications for SSD.
Available Medications
A number of pharmacological treatments exist for the treatment of psychotic disorders.
Clozapine (Clozaril), has been approved for the treatment of schizophrenia. The benefits of this
medication include effectiveness in some of those who have been resistant to treatment with
other drugs. It appears to be at least as effective as other drugs while improving both positive
and negative symptoms of schizophrenia (Ereshefsky et al., 1989). The main drawbacks include
neutropenia, a blood disorder which leaves those afflicted more susceptible to infection (in 3% of
patients), requiring stringent hematological monitoring; thereby bringing the cost of medical care
up significantly. However, improvements from the remission of severe psychotic symptoms may
justify the higher costs of Clozapine treatment. Clozapine was found to improve negative
symptoms more than Risperidone (Risperdal) in as little as three weeks (Robinson, Lieberman,
Sheitman, Alvir, & Kane, 1997).
Risperidone is among the newer atypical antipsychotic medications available. Some
researchers have indicated that it has the potential of reducing both positive and negative
symptoms with even fewer adverse effects than many other antipsychotics (Ereshefsky et al.,
2003). Its effectiveness has been relatively promising when compared to some other
antipsychotic medications (Rémillard, Pourcher, & Cohen, 2005). In addition, Risperidone is
available in a long-acting injectable form which also appears to be safe and well tolerated in
patients with schizophrenia and schizoaffective disorder (Lindenmayer, Khan, Eerdekens, Hove,
& Kushner, in press). Pharmacological studies have also taken note of behavioral problems.
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Lithium has been shown to effectively treat problem behaviors such as elevated moods and
distractibility (Aman, Collier-Crespin, & Lindsay, 2000).
A large double-blind study of atypical antipsychotic drugs examined the effectiveness of
antipsychotic drugs in patients with chronic schizophrenia. Researchers found Olanzapine
(Zyprexa) to be the most tolerable of included medications examined, having the fewest patients
discontinue because of side effects. Olanzapine was more tolerable than Risperidone,
Quitiapine, and Ziprasidone (Lieberman, Stroup, McEvoy, Swartz, Rosenheck, Perkins, et al.,
2005). Olanzapine has also been found to be very effective with negative symptoms (Emsley &
Oosthuizen, 2003). However, discontinuation rates of medications were extremely high in this
study; reportedly due to undesirable side effects including weight gain and metabolism changes.
Other studies have found improvement in negative symptoms of schizophrenia from Olanzapine
(Tollefson, Sanger, & Beasley, 1997). Olanzapine was also found to improve depressive signs
and symptoms in recovering patients with schizophrenia (Tollefson, 1997). These depressive
symptoms are noted as the most likely to improve clinical outcomes for these patients (Hogarty,
1995). A study comparing Olanzapine to Haloperidol (Haldol) and placebo found it to be
superior for treating negative symptoms (Tollefson et al., 1997)
Quetiapine (Seroquel) has been found to improve attentional, motor, and visuo-motor
skills as well as executive functioning without increasing motor side effects across a wide variety
of neuropsychological tests through eight weeks of treatment (Arvanitis & Rak, 1997).
Quetiapine appears to be an effective and well-tolerated treatment for schizophrenia (Akdede,
Alptekin, Kitis, Arkar, & Advardar, 2005).
Aripiprazole (Abilify), a recently approved second-generation antipsychotic, has also
been found to be effective and well-tolerated when combined with typical antipsychotic batteries
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used within the SSD population (DeLeon, Patel, & Crismon, 2004). Given the high rate of
polypharmacology within SSD, this is promising. However, control for additional psychotropic
drugs within this sample was not thoroughly discussed. Caution should be noted with these
results as they appear to be sponsored in part by a pharmaceutical company. Much more
research is necessary on this treatment, but it does show promise.
Researchers who have evaluated the side effects of antipsychotic drugs have increased
the quality of the literature in recent years. Atypical antipsychotics have shown promise by
having more favorable side effect profiles than those of typical antipsychotics. Fifty-one
institutionalized adults with ID participated in a study examining side effect profiles of three
groups were studied. One group had no psychotropic medication, one group was taking atypical
antipsychotics (risperidone or olanzapine), and one group took typical antipsychotic drugs
(thioridazine, chlorpromazine, or haloperidol). Utilizing the Matson Evaluation of Drug Side
Effects (MEDS) scale, the groups taking no psychotropic medications and the atypical
antipsychotics did not differ from one another on side effect measures. Both groups had
significantly fewer side effects than participants who were taking typical antipsychotics
(Advokat, Mayville, & Matson, 2000).
The focus on investigating pharmacological treatments for schizophrenia is important and
appears to have done much to improve the lives of individuals with schizophrenia. However,
one should also not ignore the behavioral and cognitive treatments for delusions and other
symptoms of schizophrenia. Related to these behavioral and cognitive treatment options are
social and adaptive variables. The importance of considering social and adaptive variables
during both the diagnostic and treatment planning process can not be overlooked (Matson,
Mayville, Lott, Bielecki, & Logan, 2003).
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Although side effect profiles have improved with the emergence of atypical
antipsychotics, adverse side effects are still an undesirable byproduct of common medications
(Lieberman et al., 2005). Cognitive and behavioral treatments do not carry the same side effects
and thus offer distinct advantages over medication. Behavioral treatments are also more likely to
be successful in treating individuals with severe ID based on their cognitive limitations.
Specifically, an increase in the frequency of verbal expressions of delusions in response to
attention, approval, and reinforcement has been documented. Making social and other
reinforcers contingent on the non-expression of delusions decreased the occurrence of delusions
(Ayllon & Haughton, 1964). A cognitive-behavioral model supported by Watts, Powell, &
Austin (1973) and Johnson, Ross, & Mastria (1977) described strategies based on modifying
attitudes, or the “ownership” of experiences individuals believe themselves to be living.
However, when dealing with clients who have limited communication skills, the utility of these
approaches are significantly reduced.
Other Considerations
One contested treatment for schizophrenia is psychotherapy – specifically
psychodynamic psychotherapy (Stone, 1986). Freud, who normally argued in favor of
psychotherapy, believed it was not suitable for individuals with schizophrenia. This view is even
more likely to be shared with severe or profound ID based on their cognitive levels (Clark,
2001). Some guidelines recommended by those who advocate for psychotherapy in the
treatment of schizophrenia would be that it should be offered only if one is capable of
responding, essentially requiring a level of verbal ability to receive a diagnosis of schizophrenia
(Kendell, 1988).
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In spite of these reservations, psychotherapy does have some support. Combination
treatments which include psychotherapy have been successfully used for those patients with
adequate communication skills successfully (Fromm-Reichmann, 1948; Normand & Bluestone,
1986). Opponents of psychotherapy point out several shortcomings of its clinical utility. The
first disadvantage has been mentioned; the requirement of communication abilities, especially
verbal, is above the level of some patients. This can be specifically due to ID, other concurrent
mental or physical illnesses, or a combination of any of these items. Also, opponents are quick
to point out that in some studies, psychodynamically orientated psychotherapy has not been
shown to have any proven value in the treatment of schizophrenia in people of normal
intelligence (Mueser & Berenbaum, 1990). Another identified shortcoming of psychotherapy is
the reported adverse effects in managing schizophrenia.
A number of treatments have been outlined and their effectiveness discussed. Within the
realm of ID, schizophrenia must be examined. There are many similarities between the general
and ID population when discussing SSD. Both will be reviewed and discussed.
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Schizophrenia in the Intellectually Disabled
Background
Formal descriptions of what appears to be schizophrenia emerged starting in the late
1800’s. W. W. Ireland described a 17-year-old female in his monograph On Idiocy and
Imbecility (1877) who ‘had some delusions, especially that a man in the neighbourhood used to
throttle little children and throw them down dead by the roadside. This, she assured me, was
quite true, in an entirely convinced voice’ (249-253). A study in 1934 also cited “much
overlapping of the respective syndromes” and further pointed out a presumed co-existence of
schizophrenia and ID in the same patient (Rosanoff, 1934). Difficulties in diagnosis were
apparent long ago and unfortunately may not be much easier today. Clinicians still struggle to
properly identify schizophrenia in the mentally retarded population.
Over the years, making the diagnosis of schizophrenia in persons with ID has been a
source of controversy and debate in the clinical literature (Turner, 1989). The controversy is
surprising, considering the DSM-IV (American Psychological Association, APA, 2000) states
“that there is no evidence that the nature of a given mental disorder is different in individuals
who have mental retardation” (p. 42).
At one time, some believed mental deficiency to be genetically linked to schizophrenia.
Kallman, Barrera, Hoch, & Kelly (1941) was among the first to disprove this notion. As a result
of this, the DSM-IV does acknowledge the difficulty involved in differential diagnosis within
this population. The positive features of schizophrenia for individuals with severe and profound
ID, at least in terms of frequency, resemble the clinical picture of schizophrenia without ID
(Johnstone & Frith, 1996). Specifically, those symptoms seem to be hallucinations, delusions,
and disorganized speech (Cherry, Penn, Matson, & Bamburg, 1999). Negative symptoms seem

17

to be markedly under-represented in this group. Bamburg et al. (1999) suggested diagnostic
overshadowing as one possibility to explain the differences found in negative symptoms between
groups. Further, Reiss, Levitan, & Szyszko (1982) discussed how the presence of ID decreases
the significance of behaviors associated with psychopathology, touching on why diagnostic
overshadowing exists in the mentally retarded population. Communication deficits complicate
nearly all diagnostic criteria, including both positive and negative symptoms of schizophrenia.
This needs to be considered when discussing difficulties found in diagnosing SSD in the ID
population.
Research involving diagnostic overshadowing has been mixed; overall there was
relatively little support in clinical research. One main concern in this area of research continues
to be methodological; although alternative approaches are suggested, oftentimes none are
specified (Mason & Scior, 2004). Studies have found that 10-59% of individuals with ID meet
diagnostic criteria for mental illness (Didomenico, 1994). Furthermore, Didomenico (1994)
found diagnostic overshadowing tends to occur in areas of personality disorders, while behavior
disorders are often attributed to ID. One meta-analysis found effect sizes across experiments
involving diagnostic overshadowing to be small to moderate (White, Nichols, Cook, & Spengler,
1995). Most research does not support diagnostic overshadowing. Another study found many
disorders believed to be commonly overlooked to be readily and commonly diagnosed (Lennox,
1996). Hunter (1995) also failed to find evidence of diagnostic overshadowing. Professional
experience was not found to have an effect on diagnostic overshadowing, but was found to
improve diagnostic accuracy; which concluded that diagnostic overshadowing is unrelated to
professional experience with individuals with ID (Reiss, 1983).

18

Diagnosing schizophrenia in persons with ID is quite difficult. This issue has been
discussed as early as 1936; Duncan et al. (1936) found 38% of hospitalized individuals with
schizophrenia to be “dull or defective”. This was criticized by Slater (1936), who stressed
difficulties in carrying out psychological tests on “retarded schizophrenics”, arguing the tests on
such people were worthless. From a genetic standpoint, Slater pointed out that prevalence rates
of schizophrenia were similar (given his information) in the normal and “defective” populations.
Further support for the lack of a genetic link between schizophrenia and ID was published by
Kallman, Barrera, Hoch, & Kelly (1940). This study did find high rates of schizophrenia in
monozygotic twins (up to 81.7%). Bleuler (1950) stated “in idiocy a number of other diseases
are involved which must not be confused with schizophrenia” (p. 287). He did not object to, or
claim, that schizophrenia is a cause of “idiocy”. However, he stated none of his patients with
schizophrenia were “idiots” (Bleuler, 1950).
Prior to the general use of operational definitions and pharmacological treatments
beginning in the 1950s, psychiatric theories were rapidly changing. Fundamentals relating to
presentation of psychosis were similar, including the belief that all forms of psychosis could
exist, that symptoms were fairly typical, and that combined conditions were a relatively likely
occurrence (Beier, 1919; Berkley, 1915; Gordon, 1918). Unfortunately, without operational
definitions, one cannot be sure the researchers were describing the same symptoms in the same
populations. James (1939) found that 11% of the ID population he sampled had definite signs of
psychosis based on signs of dissociation and mannerisms. Pollock (1945) found higher
incidence of mental illness among those with subnormal intelligence. Interestingly, the rate
declined as intelligence increased. Others found that forms of insanity were similar in “mental
defectives” and “non-defectives” (Rohan, 1946). O’Gorman (1954) found a psychosis
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prevalence rate of 29% in a mental hospital using objective criteria (e.g. seclusiveness,
mannerisms and attitudes, delusions, violence, and classical verbigeration). MacGillivray (1956)
found a 5.5% prevalence rate of psychosis in a review of 209 “idiots”. Again, one must keep in
mind the lack of operational definitions and diagnostic criteria during this time.
Due to the difficulties associated with diagnosing schizophrenia in this population,
special considerations should be taken. One commonly accepted belief is that it is important for
clinicians with special expertise in the area be involved in the diagnostic process as well as when
antipsychotic medications are used in treatment (Došen & Day, 2001).
Sturmey (1998) wrote a historical overview of psychiatric diagnoses in the ID population,
which included a review of the relationship between dual diagnosis and applied behavior
analysis. Sturmey’s review focused on the difficulty of diagnosing psychiatric disorders in
severe and profound ID patients is discussed, along with problems of making such diagnoses in
the borderline to mild ID populations. Between 1976 and 1993, the diagnosis of mild ID has
decreased greatly in the United States. However, at this same time, the label of “learning
disabilities” increased by over 200% (U.S. Department of Education, 1995). The mean IQ of
children diagnosed with learning disabilities has steadily decreased over this same time period
(Gottlieb, Alter, Gottlieb, & Wisher, 1994). Other labels listed by Sturmey are deemed to be
more socially acceptable, and the author lists such labels as; Emotionally Disturbed, Autistic
Disorder, Pervasive Developmental Disabilities, or Learning Disabled. Because of this
information, one must be wary when figures such as prevalence rates of SSD are cited across
time periods.
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Prevalence of Schizophrenia in the ID Population
Within the mild range of intellectual disability, schizophrenia occurs approximately three
times more frequently than in the general population (Heaton-Ward, 1977; Turner, 1989). As a
whole, researchers report prevalence rates twice to three times as high as the general population.
The generally accepted prevalence rate of schizophrenia in the general population is 1%
(Murray, 1986). However, as IQ level decreases, prevalence rates tend to decrease. This is best
explained as resulting from the increased difficulty involved in diagnosing schizophrenia in
patients as their IQ levels decrease (e.g., Lund, 1985; Reid, 1994).
As previously discussed, there is considerable difficulty in diagnosing schizophrenia in
the ID population (Reiss et al., 1982). A large number of cases end up being diagnosed as
Psychotic Disorder, NOS; this is often presumed to be because of the difficulties in
communication as levels of ID increase (O’Brien, 2002). Rates of psychiatric disorders
(including schizophrenia) in the ID population have been found to be higher than the general
population (Došen & Day, 2001). In fact, diagnostic rates of psychopathology in the ID
population are markedly greater than the general population (Nezu et al., 1992; Reiss, 1995;
Rojahn & Tassé, 1996). Diagnoses of Psychotic Disorder, NOS and other similar diagnoses are
more accepted as well as applicable in cases where the ability to communicate is hampered by
intellectual ability (O’Brien, 2002). This is often a result of the inability for clinicians to identify
positive symptoms as diagnostic criteria for schizophrenia, leading to diagnoses of related
psychotic disorders.
Additional reasons for the decline in prevalence rates for schizophrenia exist. Multiple
reasons exist for the transition of diagnoses of schizophrenia to those of psychotic disorders
within individuals with ID. Some believe schizophrenia manifests initially with cognitive
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impairment and is followed by psychosis. These cognitive impairments, and the associated
deficits of ID, may enhance one’s susceptibility to developing the symptoms characteristic of
schizophrenia. A third suggestion is that a common cause may give rise to both conditions, and
lastly the co-occurrence of both conditions is coincidental, although highly unlikely (Sanderson,
Doody, Best, Owens, & Johnstone, 2001) Research into biological links, such as changes in
brain volume between ID, patients with schizophrenia, or both, has been inconclusive in
determining cause/effect relationships. However, there is limited support from researchers
showing a common cause for the conditions could exist, such as meningitis or obstetric
complications, pointing out the importance of family history and genetic links (Sanderson et al.,
2001).
Deb, Thomas, & Bright (2001) found prevalence rates of schizophrenia to be 4.4% and
delusional disorder to be 1.0% within a community-based population between the ages of 16 and
64 with varying levels of intellectual disability. The overall rate of psychiatric illness was
similar to that of the general population, but schizophrenia was significantly higher than the
general population. Other studies found prevalence rates of schizophrenia to be near 3.0% (Reid,
1989a). These results all support prior prevalence rates cited by Turner (1989), Heaton-Ward
(1977), and Eaton & Menolascino (1982). Earlier studies looking at prevalence rates in hospital
settings found prevalence rates to be between 2 and 10% (Forrest & Ogunremi, 1974; Forrest,
Hay, & Kushner, 1968; Russel & Tanguay, 1981; Wright, 1982). Community samples from this
era found rates between 3 and 5% for current psychosis and 8% for lifetime prevalence (Corbett,
1979; Göstason, 1985).
The question of how SSD presents itself in persons with ID is a complex question that
appears best broken down into distinct areas. There are difficulties in how to assess for SSD and
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inherent difficulties with differential diagnosis due to significant diagnostic criteria overlap
among psychotic disorders. Within the ID population, diagnosis becomes even more difficult
due to deficits within the population.
Presentation of Schizophrenia
Overview
One area which has been relatively well researched is the age of onset of schizophrenia
within the ID population. The mean age of onset of schizophrenia within the ID population has
not been found to be different than the general population (Heaton-Ward, 1977; Hucker, Day,
George, & Roth, 1979; Reid, 1972). Disorders of thought and speech are often unexceptional in
the ID populations, although phenomenon such as echolalia can be easily determined and are not
as indicative of mental illness in ID as they are in adults of normal intelligence. Within the
severe and profound ID populations, a significant level of verbal fluency is usually required to
communicate and identify many of the major clinical symptomology associated with
Schizophrenia (Reid, 1989a) and other related disorders. Early studies have suggested that
catatonic phenomena were more prominent in individuals with ID (Heaton-Ward, 1977). Other
researchers describe alternating states of excitement and stupor, which are described as bordering
on affective psychoses and periodic catatonia (Reid & Naylor, 1976).
Assessment Schizophrenia in the ID Population
The Diagnostic Assessment for the Severely Handicapped – II (DASH-II) is an 84-item
informant based psychopathology screening instrument for persons with severe and profound ID.
Each item is scored on a 3 point scale based on frequency of behavior, duration of time the
behavior has occurred, and the severity of the behavior. This rating method includes 13
subscales representing major psychiatric disorders; 1) Anxiety, 2) Depression, 3) Mania, 4)
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PDD/Autism, 5) Schizophrenia, 6) Stereotypies, 7) Self-injury, 8) Elimination, 9) Eating, 10)
Sleep, 11) Sexual, 12) Organic, and 13) Impulse. The DASH-II has good psychometric
properties, inter-rater reliability is .86 and test-retest reliability is .84 (Matson, 1995). Norming
was originally conducted on 506 severely and profoundly mentally retarded persons from four
institutions in Louisiana and Wisconsin. Data from 658 severely and profoundly retarded Texas
residents were later added to this data.
Individual items from the schizophrenia subscale include; 1) Mood seems totally
unrelated to what is going on around him/her, 2) Talks with imaginary people or inanimate
objects such as televisions or pictures, 3) Speech is a jumble of words or ideas that make little or
no sense, 4) Hears things that are imaginary, 5) Stands or sits in bizarre or inappropriate
positions, 6) Experiences touch or other sensations on her/his skin that are imaginary, and 7)
Sees things that are imaginary.
Test-retest reliability for items in the Schizophrenia subscale were found to be 100%
agreement for the Frequency, Duration, and Severity portions. The kappa values were .58, .56,
and 1.0 respectively (Matson, 1995). Intraclass interrater reliability correlations for the seven
Schizophrenia subscale items has been found to be .46. The Frequency portion has a 93%
interrater agreement with a kappa coefficient of .22. The Duration portion has 92% interrater
agreement with a kappa coefficient of .32. The Severity potion has 97% agreement with a kappa
coefficient of .13 (Matson, 1995).
Items are scored on three dimensions; frequency, duration, and severity. Cut-off scores
of 1 SD above the mean were determined based on prevalence rates of psychopathology
previously identified in the mentally retarded population (Borthwick-Duffy, 1994a; Hamilton,
1995). Since the DASH-II is a screening instrument, it is considered better to overestimate the
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number of individuals with disorders. Initial screens may produce some false-positives, but will
keep false negatives to a minimum. Those individuals identified with clinical elevations can be
more closely examined by clinicians in order to accurately determine whether or not a
psychiatric disorder exists. This approach also helps emphasize the importance of clinician’s
judgment when determining diagnoses (Matson & Smiroldo, 1997).
Bamburg et al. (1999) found that 80% of individuals with elevated levels on the
schizophrenia subscale of the DASH-II met criteria for psychiatric disorders shared either
clinical features with schizophrenia (i.e., Psychotic Disorder NOS) or psychomotor features
consistent with neuroleptic side-effects often seen among persons with schizophrenia (i.e.,
Stereotypic Movement Disorder). Bamburg et al. (1999) concluded that the DASH-II appears to
be adequate for identifying behaviors and symptoms that are consistent with schizophrenia and is
therefore a reasonable screening tool for this disorder (Bamburg et al., 1999; Cherry, Penn,
Matson, & Bamburg, 1999). However, due to its relative lack of specificity for schizophrenia,
the DASH-II should not be used as a sole diagnostic instrument. The vital role of clinical
judgment should never be overlooked; screening instruments such as the DASH-II are useful for
identifying individuals requiring additional scrutiny regarding diagnoses. Cherry et al. (1999)
found positive symptoms including hallucinations, delusions, disorganized speech, paranoia, and
disorganized thinking. They reported negative symptoms occurring at a lower rate, and specified
flat affect, withdrawal, and anxiety-related problems as those falling under Lenzenweger and
Dworkin’s (1996) four factors of schizophrenia phenomenology.
Symptoms identified by the DASH-II which have associated scores on the Questions
About Behavior Function (QABF) can help predict whether behavioral or pharmacological
treatments will be more effective. Frequency ratings for the QABF have been found to be
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similar across age groups for four of the DASH subscales, with older adults showed longer
duration and/or greater severity ratings than younger adults (Applegate, 1999).
Dual Diagnosis
Within the mild range of intellectual disability, Reid (1989b) reported a diagnosis of
schizophrenia in a mentally retarded person can be established with reasonable certainty on the
basis of the clinical features and the natural history of the disorder. Since the early 1970s, the
literature has seen a switch from primarily diagnostic focuses in the literature to causality and
behavioral management.
Schizophrenia, as well as major mood disorders, often presents in a similar fashion to the
classic clinical presentation in the normal population (Hucker, Day, George, & Roth, 1979;
Meadows, Turner, Campbell, & Lewis, 1991; Reid 1972; Sovner and Hurley, 1983), although
the majority of this research focused on individuals with mild or moderate ID. Meadows et al.
(1991) found the age of onset tends to be earlier in individuals with mild ID. Interestingly, the
Schedule for Affective Disorders and Schizophrenia (SADS) was found to be effective for
individuals down to IQs of 50 (Meadows et al., 1991). This is preliminary evidence for
attempting to use widely accepted mainstream clinical interview in individuals with mild ID.
Empirical research is needed to justify the use of such measures in individuals with ID. Limited
research on other scales for diagnosing mental illness in the ID population exists. A study by
Hatton et al. (2005) used the Positive and Negative Syndrome Scales (PANSS) and the Psychotic
Symptom Rating Scales (PSYRATS) on a population with mild ID and psychiatric diagnoses
based on ICD-10 diagnostic criteria. Both scales were able to differentiate between a psychotic
population and a non-psychotic population based on auditory hallucination subscales. However,
the PANSS negative symptoms subscale and the PSYRATS delusions subscales did not
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differentiate between groups. The authors felt the assessments were promising for positive
symptoms, but caution is needed regarding negative symptoms. A better tool for negative
symptoms may be the Scale for Assessment of Negative Symptoms (SANS; Andreasen, 1989a;
Andreasen 1989b). This measure is based on ICD-10 criteria, indexing affective blunting,
alogia, avolition/apathy, anhedonia/asociality, and disturbances of attention. Items are ranked on
a six-point scale, have good reliability, and correlates well with the PANSS (Bouras, Martin,
Leese, Vanstraelen, Holt, Thomas, et al., 2004).
Based on the existing research, it is easy to conclude that little research has been done in
the area of schizophrenia within the severe and profound ID population. Research reiterates the
problem of language deficits hampering or precluding self-reports of delusions, hallucinations,
and other expressions of disordered thought that are the hallmark diagnostic criteria of
schizophrenia (Cherry et al., 1999). Their work followed the Lenzenweger and Dworkin (1996)
four-factor structure of schizophrenia phenomenology, comparing symptoms within the severe
and profound range of ID to those with normal intelligence. The researchers hypothesized that
evidence showing similarity of symptoms may help identify common signs of schizophrenia and
assist in developing empirically-based criteria for diagnosing schizophrenia within this
population.
Differential Diagnosis
Notable facts regarding schizophrenia presentation in the severe and profound range of
ID emerged from result of Cherry et al., (1999). Negative symptoms were reported to have
occurred, but they were reported at a lower level than those involving reality distortion or
disorganizations. The most prevalent negative symptoms reported included flat affect,
withdrawal, and anxiety-related problems. A range of positive symptoms emerged, primarily
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hallucinations, delusions, and disorganized speech. In terms of frequency, the positive features
of schizophrenia resemble the clinical picture of schizophrenia without ID (Cherry et al., 1999).
However, negative symptoms were reported to be considerably under-reported when compared
to adults of normal intelligence. Diagnostic overshadowing was discussed as it may influence
the identification of negative symptoms such as flat affect and withdrawal. The problem of how
these lower reported rates of negative symptoms may be explained by how the information is
obtained. An alternative hypothesis to explain the difference in symptom presentation was
offered by Cherry et al. (1999). Symptom information is often obtained from psychiatric reports,
which often have a bias favoring overt behaviors. These behaviors are often the positive
symptoms, which staff find disturbing and do not focus on the negative symptoms less
troublesome to caretakers. Ultimately, the difference in presentation may be an artifact of
positive symptoms causing excess work and problems compared to negative symptoms, which
generally require less attention and effort from caregivers.
Direct observations by properly trained and neutral third parties may be useful in
obtaining a more accurate estimate of the presentation of both positive and negative symptoms of
schizophrenia. An interesting theory discussed included a shift of the diagnosis of schizophrenia
to concentrating on specific symptoms presented by patients. Even though there is a relative lack
of specificity for the DASH-II on schizophrenia and its ability to identify specific symptoms
presented in both schizophrenia and psychosis, it may have excellent clinical utility to identify
symptoms to target for treatment (Cherry et al., 1999).
A study involving assessment of schizophrenia in the profound ID population using the
DASH-II contributed a few major findings to the literature. Using the DASH-II, it is possible to
differentiate between those who are diagnosed and have an elevation on the schizophrenia
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subscale and those who either have an elevation on the schizophrenia subscale without a
diagnosis, as well as those with only profound ID, on the endorsement of items related to verbal
behavior. It also seems to be sensitive to symptoms consistent with psychotic disorders
(Bamburg et al., 2001).
Matson et al. (2003) found that schizophrenic adults had significantly higher scores in
Independent Living Skills of the Vineland Adaptive Behavior Scales (VABS) (Sparrow et al.,
1984) than the general ID population. Other research supports these results, finding that social
skills are often adequate or strengths of those diagnosed with schizophrenia (Mueser & Bellack,
1998).
Schizophrenia has been found to have significant impacts on the adaptive functioning of
those with the disorder. Instruments such as the VABS look specifically at the areas of
communication, daily living skills, and socialization. Other deficits with significant effects on
individuals’ lives exist. Behavior problems, one such area that affects many areas of individuals’
lives, is the focus of this research.
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Behavior Problems with Intellectually Disabled
Overview
Individuals with ID often present with a multitude of behavioral problems. These
maladaptive behaviors are often defined as behaviors which interfere with how a person executes
tasks expected of them (Morreau, 1985). Among individuals with ID there is a significantly
higher risk for displaying problem behaviors. These problem behaviors include, but are not
limited to, self-injurious behavior, aggression, disruption, and stereotypic behaviors (BorthwickDuffy, 1994b; Borthwick-Duffy & Eyman, 1990; Rojahn, Borthwick-Duffy, & Jacobson, 1993)
and maladaptive behaviors (Eyman & Borthwick, 1980).
Problem behaviors can be classified in multiple ways, which further complicates research
as different assessment scales often break behaviors into different subscales. Some ways in
which behavior problems are commonly grouped include: hurtful to self, hurtful to others,
destructive to property, disruptive behavior, unusual or repetitive habits, socially offensive
behavior, withdrawal or inattentive behavior, and uncooperative behavior (McGrew et al., 1991;
McGrew & Bruininks, 1989; Meyers, Nihira, & Zetlin, 1979; Morreau, 1985).
Problem behaviors have also been found to increase in severity and frequency as ID
levels increase (Jacobson, 1988). Aberrant behavior disorders (e.g., stereotypies, SIB,
elimination disorders, eating disorders, sleep disorders, sexual disorders, impulse control, and
organic syndromes) are commonly diagnosed within the severe and profound ID groups (Cherry,
Matson & Paclawskyj, 1997). Interestingly, impulse control disorders were identified in over
half the sample in this study.
Past studies have shown some of these previously mentioned problem behaviors (selfinjury and aggression) as well as less frequently cited behavior problems (pica) may be
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maintained by a number of variables. These variables include variables in the environment (e.g.,
attention, escape, tangibles) as well as non-social factors (e.g. sensory stimulation) (Durand &
Crimmins, 1988; Iwata, Dorsey, & Slifer, 1982).
Additional problem behaviors have been identified utilizing the Questions About
Behavior Function (QABF; Paclawskyj, Matson, Rush, Smalls, & Vollmer, 2000). The QABF is
another assessment tool aimed at identifying the function of behaviors. In this study, numerous
behavior problems were reviewed and their functions were examined. Within the severely and
profound ID populations, this study identified behavior problems less often cited in the literature.
These behaviors included pica, rumination, food stealing, and food refusal in addition to those
commonly cited such as aggression and self-injurious behavior (Applegate, Matson, & Cherry,
1999).
Prevalence Rates
Prevalence rates of behavior problems have been documented for individuals with ID. A
sample of over 400 institutionalized adults found prevalence rates of at least one problem
behavior to be approximately 73%. Similar prevalence rates were found in a study examining a
special care district in Finland using the Behavior Problems Inventory. Over 250 adults were
studied and a prevalence rate of 70% was found for behaviors considered to be “more than a
mild problem”. Roughly 10% of these behaviors were deemed to be potentially dangerous
(Saloviita, 2002).
Behavior problems are more common in the ID population than the general population;
furthermore these behavior problems are often quite serious (Borthwick-Duffy & Jacobson,
1993; Matson, Hamilton, & Duncan, 1997; Rojahn, 1986; Schroeder, Rojahn, & Oldenquist,
1991) and are oftentimes among the predominant reasons for institutionalization (Harrow, 1987;
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Clark, 2001). Deeper understanding of what problems are present in this population is likely to
aid in treatment and increase quality of care for patients suffering from SSD (Emerson, 2001).
The factor structure of problem behaviors in persons with ID has been examined by many
researchers. However, determining what areas problem behaviors should be categorized in
proves to be difficult. Some researchers have categorized these problem behaviors into only a
few areas (Rojahn, Matson, Lott, Esbensen, & Smalls, 2001). In this study, three factors of
problem behaviors were identified. Stereotyped behaviors were found at a prevalence rate of
54%, self-injury at a rate of 43%, and aggressive/destructive behaviors at a rate of 38% (Rojahn
et al., 2001). However, not all researchers believe problem behaviors should be categorized so
simply. Other classifications include: hurtful to self, hurtful to others, destructive to property,
disruptive behaviors, uncooperative behaviors, unusual or repetitive habits, socially offensive
behavior, withdrawn or inattentive behavior, and uncooperative behavior (McGrew, Ittenbach,
Bruininks, & Hill, 1991; McGrew & Bruininks, 1989; Meyers et al., 1979, Morreau, 1985).
Global prevalence rates for specific behaviors have been identified in previous studies.
Within the intellectually disabled population, aggression rates have been found to be 2.1%; selfinjurious behavior to be 9.3%, and property destruction to be 7.1%. Within institutional settings,
prevalence rates appear to be even higher. Aggression rates are reported to be 12.8%, selfinjurious behavior to be 31.2%, and property destruction to be 29.6%, (Borthwick-Duffy, 1994).
These rates tend to be consistent with those reported in the literature. One additional behavior
problem noted was making loud noises and swearing, but prevalence rates were not reported for
this behavior (Joyce, Ditchfield, & Harris, 2001). In day program settings, the most commonly
experienced problem behaviors are found to be agitation, irritability, stereotypic behaviors,
hyperactivity, and noncompliance (Galli, Fabienne, & Nadine, 2005).
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Three possible ways problem behaviors have been associated with general psychiatric
disorders have been proposed. One suggestion reason is that they represent the atypical
presentation of the disorder’s core symptoms. The second possibility is that these problem
behaviors are occurring as a secondary feature of psychiatric disorders. The third possibility that
the psychiatric disorders act as establishing operators for operant-maintained problem behaviors
(Emerson, 2001). Certainly the third item warrants consideration given the earlier discussed
links between problem behaviors and living situations. Once problem behaviors are properly
identified, functional analysis can help identify items maintaining problem behaviors. The link
to treatment planning is clear.
It has been established that individuals with ID are more prone to developing mental
illness (Borthwick-Duffy, 1994a; Galli et al., 2005); they are also prone to develop serious
maladaptive behaviors including self-injurious behavior, stereotypies, and aggression (Rojahn et
al., 1993; Schroeder, Rojahn, & Oldenquiest, 1991). Higher psychopathology scores on the
DASH-II have been linked with higher rates of maladaptive behaviors such as self-injurious,
stereotyped, or aggressive/destructive behaviors (Matson et al., 1997). Samples with ID and
schizophrenia spectrum disorders would be expected to have higher scores on the Behavior
Problems Inventory (BPI) than control groups without psychopathology.
Assessment Instrument
The current version of the BPI, the BPI-01, was originally designed as a survey
instrument in the 1980s (Rojahn, 1984; 1986). To reduce confusion, the BPI-01 will be referred
to as the BPI for the remainder of the manuscript. The scale has been refined multiple times over
the years. The current three-subscale structure with a total of 49 items was validated by
confirmatory factor analysis (Rojahn et al., 2001). The BPI focuses on three areas of
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maladaptive behaviors: self-injurious behaviors, aggressive/destructive behaviors, and
stereotyped behaviors. Identification of these problems is the first step in reducing them in order
to improve the quality of life for these individuals. Schizophrenia has previously been
moderately linked to the stereotyped behavior subscale of the BPI (Rojahn, Matson, Naglieri, &
Mayville, 2004); although SSD have not been specifically sampled against other groups for
comparison purposes. The author heartily agrees with the statement by Rojahn et al. (2004) that
“behavior problems among individuals with predominantly severe to profound ID are
significantly, positively, and clinically meaningfully related to certain psychiatric conditions.” (p.
34). This topic warrants much more attention by researchers.
According to accepted definitions, self-injurious behaviors are those behaviors which can
cause damage to one’s own body and occur repeatedly in unvarying presentation (Rojahn et al.,
2001). Stereotyped behaviors are peculiar or inappropriate voluntary acts, which occur
habitually and repetitively. Aggressive or destructive behaviors are abusive, deliberate attacks
against other individuals or objects. Reliability and validity for the BPI has been found to be
reasonable (e.g. Rojahn et al.; 2001, Sturmey, Fink, & Sevin, 1993; Sturmey, Sevin, & Williams,
1995). The BPI also has very high inter-interviewer agreement as well as test-retest reliability in
the “good” to “excellent” range (Rojahn et al., 2001).
Characteristics
As previously noted, there is a lack of research investigating how behavior problems
affect adults with ID and SSD (Bleuler, 1950; Heaton-Ward, 1977; Turner, 1989). Problems
within the research exist; inclusion criteria have been vague and operational definitions lacking
(Heaton-Ward, 1977). Bleuler was one of the skeptics of diagnosing schizophrenia in the ID
population; cautioning clinicians of the differences between catatonia and stereotyped behavior.
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He insisted great care be taken in the process of differential diagnosis. His insight into the
difficulties involved in differential diagnosis is still relevant today.
Some headway has been made in our ability to diagnose and understand schizophrenia;
we are now better able to diagnose schizophrenia in individuals with severe and profound ID,
which was not believed possible two decades ago (Reid, 1989b). Behavior problems are among
the most easily identifiable factors restricting living environments and have major influences
over daily living situations, quality of life, ability to maintain employment, and placement in
more restrictive living environments (Harrow, 1987; Clark, 2001). Higher rates of behavior
problems have been linked to higher rates of reinstitutionalization of individuals with ID
(Intagliata & Willer, 1982). Research focusing on identifying what the common behavior
problems are for individuals with SSD and ID compared to other individuals within
institutionalized settings is needed.
Because of the issues arising from instituting behavioral treatment plans in institutional
settings, there is a need to discuss acceptability of treatments. Hastings, Boulston, Monzani, &
Tombs (2004) claim reinforcement based interventions (DRO, DRA, etc.) as well as less
intrusive interventions are rated as more acceptable to staff. These staff are key to the
effectiveness of treatment plans, so their acceptance is likely to lead to better plan followthrough. Interestingly, the acceptable level of intrusiveness was found to increase with the
severity of the problem behavior (Hastings et al., 2004).
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Purpose
Identification of behavior problems are among the most important impediments involved
in the placement of individuals with ID into the community (Intagliata, 1982). Proper
identification of behavior problems should therefore help treatment planning (Harrow, 1987;
Clark, 2001) as well as placement in less restrictive living environments. Further, comorbid
psychopathology may prove to be a factor that further exacerbates these behaviors. Certainly,
better understanding the relationship between ID, comorbid psychopathology, and behavior
problms is a high stakes proposition given the implications of challenging behavior for these
individuals’ quality of life. One particularly serious group of comorbid disorders, likely to
receive highly invasive medication and psychological interventions are SSD. Therefore, the
principle goal of this study was to evaluate the implications of SSD on ID adults with
challenging behaviors when compared to persons with other forms of psychopathology and ID
and behavior problems alone. If differences were found across groups, then an analysis of
specific behaviors that differentiate these groups would be valuable. Knowing the specific
challenging behavior difference might further illuminate factors that could prove fruitful in better
understanding etiology, assessment, and treatment.
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Methodology
Participants
Participants in this study were residents at Pinecrest Developmental Center (PDC) in
Pineville, Louisiana and Columbia Developmental Center (CDC) in Columbia, Louisiana. PDC
is a state-run facility that provides 24-hour supervision to nearly 575 individuals with varying
levels of ID and adaptive functioning and CDC provides the same services to nearly 60
individuals. Individuals residing at PDC and CDC also represent a variety of ages, races, and
backgrounds. Participants in this study included both males and females. All diagnoses were
provided by licensed clinical psychologists and/or board certified psychiatrists and were based
on DSM-IV-TR criteria.
The disorders included in this study as “SSD” include Schizophrenia, Schizoaffective
Disorder, Schizophreniform Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder,
Psychotic Disorder Due to a General Medical Condition, Psychotic Disorder Not Otherwise
Specified, and Substance-Induced Psychotic Disorder. A power analysis was conducted using
G-Power, a software package designed to assist in estimating required sample sizes for proper
experiments. Using an alpha level of .05 with a medium effect size (.50) and the recommended
power of .80 (four times 1-alpha), the sample size required for this level of power would be 128.
Achieving this level of power was not possible for this experiment, as this is a relatively
uncommon group of disorders. Because of the limits in SSD group participants, the other
psychopathology group and no psychopathology group each consisted of as many participants as
could be included in the SSD group. The sample size originally consisted of approximately 22
participants per group. The total sample size originally was 66 participants, but after inclusion
criteria were considered, the final sample included 42 participants.
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Three groups of individuals with ID participated in this study. These groups included
individuals with both ID and SSD, ID and psychopathology not included in the SSD group, and
individuals with ID with no psychopathology or elevations on any of the DASH-II subscales to
serve as a control. All subjects met criteria for a DSM-IV-TR diagnosis as determined by a
licensed Psychologist or a board certified Psychiatrist. The SSD group required further inclusion
criteria of an elevation on the DASH-II Schizophrenia subscale to insure proper group
placement. The other psychopathology group was added to insure that behavior problems
measured are due to the SSD and not linked to general psychopathology within individuals with
ID.
A total of 22 subjects per group were included in the initial data pool. Analysis of current
signs of psychopathology via the DASH-II left 14 participants per group meeting inclusion
criteria for this study, totaling 42 subjects in the final subject pool. Demographic characteristics
of the final sample population are presented in Table 1. Participants were matched on
demographic variables including age, level of ID, gender, presence or absence of psychotropic
medications, visual impairments, and auditory impairments. Chi-square analysis was conducted
to assess whether there was a difference in psychotropic mediations between groups. The results
of the test were significant, X2(3, N = 42) = 10.27, p<.01. Results of chi-square analyses found
no significant differences on any remaining matched variables.

Table 1
______________________________________________________________________________
Demographic Characteristics of Groups (N=42)
______________________________________________________________________________
SSD (n=14)
Psychopathology
Control (n=14)
(n=14)
Age
0-20
0 (0%)
0 (0%)
0 (0%)
21-40
4 (28.6%)
0 (0%)
2 (14.2%)
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41-60
61+

7 (50.0%)
3 (21.4%)

10 (42.9%)
4 (28.6%)

7 (50.0%)
2 (14.2%)

Female
Male

9 (64.3%)
5 (35.7%)

9 (64.3%)
5 (35.7%)

9 (64.3%)
5 (35.7%)

Mild
Moderate
Severe
Profound

3 (21.4%)
5(35.7%)
4 (28.6%)
2 (14.2%)

2 (14.2%)
5(35.7%)
4 (28.6%)
3 (21.4%)

2 (14.2%)
5(35.7%)
4 (28.6%)
3 (21.4%)

Visual Impairment
Yes
No

0 (0%)
14 (100%)

1 (7.1%)
13 (92.9%)

0 (0%)
14 (100%)

Auditory Impairment
Yes
No

0 (0%)
14 (100%)

0 (0%)
14 (100%)

0 (0%)
14 (100%)

Psychotropic Medications
Yes
No

13 (92.9%)
1 (7.1%)

11 (78.6%)
3 (21.4%)

1 (7.1%)
13 (92.9%)

Gender

Level of ID

Many participants had multiple axis I diagnoses. Only one of the SSD participants had
more than one axis I diagnosis, while the psychopathology group had five participants with
multiple axis I diagnoses. Within the SSD group, five participants were diagnosed with
schizophrenia, five with psychotic disorder, NOS, two with schizoaffective disorder, and two
with delusional disorder. One participant within the SSD group had a comorbid anxiety disorder.
Two participants the psychopathology group were diagnosed with anxiety disorders. One
participant in the psychopathology group was diagnosed with attention-deficit/hyperactivity
disorder and another had a diagnosis of conduct disorder. Two participants were diagnosed with
autistic disorder and two more with pervasive developmental disorder, NOS. Five participants in
the psychopathology group were diagnosed with bipolar disorder. Two participants in the
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psychopathology group were diagnosed with depressive disorders and two more with mood
disorders. Two participants in the psychopathology group were diagnosed with stereotypic
movement disorder. The control group had no axis one diagnoses, by definition.
Measures
The Diagnostic Assessment for the Severely Handicapped – II (DASH-II). The DASH-II
was used for participant selection and group assignment. The DASH-II is a psychopathology
screening instrument for use in the ID population (Matson, 1995). The DASH-II contains 13
subscales: (1) autism and other pervasive developmental disorders, (2) organic syndromes, (3)
anxiety, (4) mood disorders, (5) mania, (6) schizophrenia, (7) stereotypies and tics, (8) selfinjurious behavior, (9) elimination, (10) eating disorders, (11) sleep disorders, (12) sexual
disorders, (13) impulse control and other miscellaneous behaviors. Each item is scored on its
frequency in the prior two weeks (not at all = 0, between 1 & 10 times = 1, more than 10 times =
2) as well as the length of time the behavior has occurred (less than one month = 0, between 1
and 12 months = 1, over 12 months = 2) and its severity (caused no disruptions or damages = 0,
caused no damages but interrupted the activities of peers, family, or staff members at least once
= 1, caused injury or property damage at least once = 2).
Behavior Problems Inventory (Rojahn, 2001). The BPI is an informant-based behavior
rating scale for observable behavior problems in individuals with ID. This measure consists of
three subscales: self-injurious behavior, stereotyped behavior, and aggressive/destructive
behaviors. The Self-Injurious Behavior subscale contains 14 items, the Stereotyped Behavior
subscale contains 24 items, and the Aggressive/Destructive Behavior subscale contains 11 items
(Rojahn et al., 2004). Observed behaviors must have occurred one or more times within the
previous two months. Each item is scored on two scales, a five point frequency scale (never = 0,
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monthly = 1, weekly = 2, daily = 3, hourly = 4) and a four-point severity scale (no problem = 0, a
slight problem = 1, a moderate problem =2, a severe problem = 3). In order to shorten item
definitions, each of the three subscales is precluded by generic definitions applying to all items
within the subscale.
Procedure
The investigator was trained on the administration of the DASH-II and BPI in accordance
with the procedures outlined in their respective administrative manuals. Data was collected with
these measures from direct-care staff at the Pinecrest Developmental Center and Columbia
Developmental Center. Informants used in this study were familiar with and worked with the
participant for at least six months prior to data collection. Both measures were administered to
the same informant to decrease the likelihood of inter-rater error occurring. Both the DASH-II
and BPI were administered for the same participant within the same week.
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Results
Data were included for all experimental subjects meeting inclusion criteria of clinical
elevations on the DASH-II Schizophrenia subscale and their matched triads. A multivariate
analysis of variance (MANOVA) was performed on the data obtained from the BPI in order to
determine whether the three diagnostic groups differed on the frequency or severity any of the
three dependent factors as well as the total frequency and severity scores of the BPI. The 3 x 8
MANOVA was conducted with three subject groups and three subscale groups of the BPI as well
as an overall score on the BPI as dependent variables. Both frequency and severity of
endorsements were evaluated for these items.
The results of Wilks’ Lambda test on the BPI suggest a significant main effect of
diagnostic group, Wilks’ Λ = .38, F(7,33) = 2.92, p < .05. Thus, the null hypothesis which
states that no differences in behavior problems would be found across groups does not hold.
Significant main effects were found for the frequency F(2,39) = 5.43, p < .05 and severity
F(2,39) = 5.15, p < .05 of the Stereotyped Behavior subscale of the BPI. Significant main effects
were found for the overall frequency F(2,39) = 4.28, p < .05 and overall severity F(2,39) = 4.79,
p < .05 of BPI scores. In addition, the severity of Aggressive/Destructive Behaviors approached,
but did not reach, statistical significance F(2,39) = 2.98, p= .068. Results of the MANOVA are
summarized in Table 2 below.
Table 2
Significance of BPI values across groups
___________________________________________________________________________
BPI Behavior
F Value
p-value

SIB
Frequency
Severity

1.96
2.01
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.16
.15

(Table 2 cont.)
Stereotypies
Frequency
Severity

5.43
5.15

.01a
.01a

Aggressive/Destructive Behavior
Frequency
Severity

0.95
2.88

.40
.07

Total Frequency

4.28

.02a

Total Severity
Note. a Significant omnibus tests

4.79

.01a

In order to more closely examine observed differences from the MANOVA, post-hoc
pair-wise comparisons were conducted with the group means on each significant subscale. The
Student Newman-Kuels (SNK) test was chosen because of its greater power than the Tukey HSD
test (Hinkle, Wiersma, & Jurs, 2003). The increase in power comes at the cost of a minimal
increase over the a priori alpha level set in the original MANOVA.
Significant mean differences were found on the frequency and severity scores of the
Stereotypy Subscale The SSD and psychopathology groups had significantly higher mean
endorsements on Stereotypy frequency subscales than the control group, p<.05. The
psychopathology group did not differ significantly from control group (p=.15) or the SSD group
(p=.09) on severity on the Stereotypy subscale. The difference between the SSD and
psychopathology groups were non-significant for frequency of stereotypies (p=.36) and severity
of stereotypies (p=.09). The SSD group differed significantly from the control group (p<.05) but
not the psychopathology group (p=.34) on overall frequency of stereotypies and severity of
stereotypies (p=.15). These results are summarized in Table 3.
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Table 3
BPI scores.
_____________________________________________________________________________
BPI Group
SSD
Psychopathology
Control
SIB
Frequency
Severity

2.93
1.86

2.71
2.50

0.71
0.57

Stereotyped Behavior
Frequency
Severity

13.0a
7.79a

9.71b
4.14b

1.71a,b
1.07a,b

5.78
5.79

3.71
2.86

2.86
1.36

Aggressive/Destructive
Behaviors
Frequency
Severity

Overall BPI Scores
Frequency
21.71a
16.14b
5.29a,b
a
b
Severity
15.43
9.50
3.00a,b
______________________________________________________________________________
Note. Scores in a row sharing superscripts are significantly different at p < .05. For all subscales,
higher means indicate higher symptom endorsements.
Specific items were analyzed with pair-wise comparisons on group means in order to
determine if behaviors differed across groups for each behavior in either frequency or severity.
There were no differences between groups within the Self-injurious Behavior subscale for
frequency or severity. Within the Stereotyped Behaviors subscale, differences were found
between groups. The SSD group scored higher on frequency of waving or shaking arms than the
control group, p<.05. The psychopathology group approached, but did not meet significance for
differences from the SSD group (p=.06), but was different from the control group (p=.49). The
SSD group scored higher on frequency of having repetitive body movements than the control
group (p<.05). The psychopathology group did not differ from the SSD group (p=.54) or the
control group (p=.06). The SSD group and psychopathology group scored higher than the
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control group on frequency of repetitive hand movements (p<.05) but not each other (p=.81).
The SSD group scored higher than psychopathology and control groups in frequency and
severity of grimacing (p<.05), whereas the psychopathology and control groups did not differ in
terms of frequency (p=.68) or severity (p=.77).
Within the Aggressive/Destructive Behavior subscale, only one item had significant
differences between groups. The SSD group differed significantly from the psychopathology
and control groups on frequency and severity of being verbally abusive with others (p<.05). The
psychopathology and control groups did not differ on frequency (p=.77) or severity (p=.46) of
being verbally abusive with others. Post-hoc scores are summarized in Table 4 for specific items
found to differ based on group membership.
Table 4
Mean scores for specific BPI items.
_____________________________________________________________________________
BPI Group
SSD
Psychopathology
Control
Waving or shaking arms
Frequency
Severity

1.07a
0.50

0.29
0.21

0.00a
0.00

Engaging in repetitive body movements
Frequency
1.50a
Severity
0.71

1.14
0.50

0.00a
0.00

Having repetitive hand movements
Frequency
1.50a
Severity
0.57

1.36b
0.57

0.00a,b
0.00

0.14a
0.07a

0.00b
0.00b

Grimacing
Frequency
Severity

0.86a,b
0.64a,b

Being verbally abusive with others
Frequency
1.71a,b
0.57a
0.43b
a,b
a
Severity
1.64
0.50
0.21b
Note. Scores in a row sharing superscripts are significantly different at p < .05. For all subscales,
higher means indicate higher symptom endorsements.
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Convergent validity between the stereotypy-related of both measures was examined.
Results of chi-square analysis found significant correlations between items of both scales.
Significant positive correlations were found for the DASH-II item involving repetitive body
movements (item 31 in Table 5) with BPI items involving specific repetitive movements, such as
rolling one’s head (r(41) = .42, p<.05), repetitive hand movements (r(41) = .63, p<.05), complex
hand/finger movements (r(41) = .73, p<.05), repeatedly manipulating objects (r(41) = .39,
p<.05), and sustained finger movements (r(41) = .75, p<.05). In addition, correlation with a
nearly identical item, having repetitive body movements, was extremely high (r(41) = .67,
p<.05).
The DASH-II item involving sustained motor activities (item 36) also showed good
convergent validity. From the BPI, pacing was highly correlated with this item (r(41) = .65,
p<.05), as was yelling/screaming (r(41) = .66, p<.05), bursts of running around (r(41) = .67,
p<.05), manipulating objects repeatedly (r(41) = .34, p<.05), sustained finger movements (r(41)
= .32, p<.05), grimacing (r(41) = .53, p<.05), and waving/shaking hands (r(41) = .54, p<.05).
The DASH-II items involving repeating words and sounds (item 41) and talking about
the same subject/concern repeatedly (item 49) also showed convergent validity with the single
verbal related BPI item, yelling/screaming, (r(41) = .32, p<.05), (r(41) = .65, p<.05) respectively.
Two items on the DASH-II did not correlate well with the BPI stereotypy items. Items
involving collecting/hoarding objects and sucking/mouthing parts of one’s body correlated with
1 and 0 items on the BPI stereotypy subscale respectively. Hoarding items correlated highly
with repeatedly manipulating objects on the BPI (r(41) = .40, p<.05). Thus, these measures seem
to have good divergent validity as well. Complete correlations for all stereotypy items can be
found in Table 5 below.
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Table 5
Pearson correlation coefficients between frequencies of BPI Stereotyped Behavior and DASH-II
Stereotypies subscales
_____________________________________________________________________________
DASH 21 DASH 28 DASH 31 DASH 36 DASH 41 DASH 49 DASH 77
BPI 16

.22

-.15

.30

.10

-.24

-.06

-.06

BPI 17

-.06

-.10

-.08

-.11

.12

-.17

-.04

BPI 18

-.06

.21

.21

.17

.08

.04

-.04

BPI 19

.17

-.17

.11

.11

.27a

.31a

-.06

BPI 20

-.04

-.07

.42a

-.08

-.11

-.12

-.03

BPI 21

-.06

-.10

-.08

-.11

-.15

-.17

-.04

BPI 22

-.15

-.05

.76a

.25

.20

.32a

.30

BPI 23

.23

.07

.32a

.65a

.31a

.34a

-.07

BPI 24

-.04

-.07

-.06

-.08

.08

-.12

-.03

BPI 25

.10

-.07

.63a

.31

.33a

.27a

.29

BPI 26

.19

.06

.31

.66a

.32a

.65a

.17

BPI 27

-.04

-.07

-.06

.31

.28

-.12

-.03

BPI 28

.57a

.14

-.08

.20

.20

.16

-.03

BPI 29

-.04

-.07

-.06

-.08

.08

-.12

-.03

BPI 30

.38a

.10

.11

.67a

.48a

.41a

-.04

BPI 31

-.07

-.12

.73a

.04

-.18

-.07

-.04

BPI 32

-.05

.40a

.39a

.34a

.29

.18

-.03

BPI 33

-11

.08

.75a

.32a

.23

.18

-.06

BPI 34

.40a

-.14

.13

.28

.34a

.18

-.05

BPI 35

.23

.01

.59a

.47a

.29

.22

-.08
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BPI 36

-.06

-.10

-.08

.08

.08

-.03

-.04

BPI 37

-.04

-.07

-.06

-.08

.04

-.12

-.03

BPI 38

.36a

-.15

.26

.53a

.22

.36a

-.06

BPI 39

.51a

.21

.21

.54a

.39a

.33a

-.04

a

Significant correlations at p<.05
In order to examine whether the severity of symptoms on the schizophrenia subscale of

the DASH-II and the severity of challenging behaviors on the BPI covary, two analyses of
covariance (ANCOVA) were conducted. The first ANCOVA was conducted with group
membership as the independent variable, the total severity score on the Schizophrenia subscale
of the DASH-II as the covariate, and the total frequency score from the BPI as the dependent
variable. Results of the ANCOVA indicated that total frequency scores from the BPI did covary
with frequency scores from the Schizophrenia subscale of the DASH-II, F(2,38) = 5.90, p<.05.
The second ANCOVA was conducted with group membership as the independent
variable, the total severity score on the Schizophrenia subscale of the DASH-II as the covariate,
and the total severity score on the BPI as the dependent variable. Results of the ANCOVA
indicated that the scores total severity scores from the BPI did not covary with severity scores
from the DASH-II, F(2,38) = 1.74, p=.19.
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Discussion
Behavior problems specific to individuals with ID and comorbid psychopathology were
the primary purpose of this study. Specific behavior problems in the SSD population and general
psychopathology differed from controls, a new and significant finding within the population
studied. Previous research mostly focused on comorbid Axis I disorders, but not behavior
problems associated with these disorders (Borthwick-Duffy, 1994a). Despite the SSD group not
having a unique behavior problem profile; these data suggest that targeting behaviors for
individuals with psychopathology and ID could be effective for successful transitions into less
restrictive placements (Harrow, 1987; Clark, 2001). Specifically, both the SSD and
psychopathology groups evinced higher scores than the control group on both frequency and
severity of items on the Stereotyped Behavior subscale of the BPI. Furthermore, when total
behavior problems endorsed on the BPI were examined, the SSD and psychopathology groups
were found to be higher than for controls on frequency and severity. These differences were not
found on the Self-injurious Behavior subscale, although differences in the
Aggressive/Destructive subscale did approach significance. These results highlight one area
found to differentiate behavior problems based on the presence of psychopathology, while
identifying another area which may warrant further investigation. Studies utilizing greater
sample size would be useful to further investigate the Aggressive/Destructive behavior subscale,
as it approached significance even with this small sample.
Analysis of correlational data suggested good convergent validity between subscales of
the BPI and DASH-II examining stereotypies within the ID population. Questions on the
DASH-II Stereotypies subscale generally encompassed multiple BPI questions. Therefore, the
high but not perfect correlations on more specific BPI questions might be expected given more
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specific data. High correlations were found between expected items on the measures. For some
DASH-II items, significant correlations with BPI items were not found. Examination of these
DASH-II items revealed them to be independent of items from the BPI, showing good divergent
validity as the BPI does not closely address behaviors such as hoarding or hand-mouthing.
Many potential explanations exist for differences found between groups. Much existing
research compared only a specific disorder to a control group, and not against a group with other
Axis I diagnoses (Emerson, 2001; Forrest et al., 1974). These groups are often medicated and
have a host of behaviors which may or may not be related to their diagnoses (Singh, Matson,
Cooper, Dixon, & Sturmey, 2005). One interesting finding is that the SSD and psychopathology
were medicated, often to help control challenging behaviors. Despite medication, behavior
problems were still significantly higher than for controls. These findings are significant for a
number of reasons. This could mean that very serious problem behaviors are only partially
controlled with these medications. How serious would these behaviors would be if patients were
without medication? Considering the difficulties with medication compliance in this population
(Lieberman et al., 2005), investigating the differences if behaviors between a group of medicated
individuals with SSD, a group that is not prescribed medication for SSD, and a previously but
not currently medicated group could provide insight into the role of medication on behavior
problems within the ID population.
Another possibility to consider is that these medications are less effective than generally
believed. Although the sample size is small, evidence of significantly higher rates and severities
of problem behaviors were found in a group with a specific disorder as well as a group with
general psychopathology. Both groups were medicated significantly more often than the control
group, yet behavioral differences remained. The question of whether resources may be better
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spent on other aspects of patient care as opposed to the heavy reliance on medication certainly
warrants attention. The effectiveness of antipsychotic medications treating specific symptoms of
SSD are consistently upheld in studies, despite findings of studies of behavior problems in the ID
population (Akdede et al., 2005; Arvanitis, 1997; DeLeon et al., 2004; Duggan et al., 1999;
Emsley et al., 2003; Ereshefsky et al., 1989; Foote, 1958; Lindenmayer et al., in press; Rémillard
et al., 2005; Robinson et al., 1997; Tollefson et al., 1997). These findings suggest medication
may be effective in reducing many of these troublesome behaviors, but not alleviating these
symptoms. Behavioral approaches to treatment in conjunction with this pharmacological
approach seem appropriate, including skill building and social skills training (Matson &
Andrasik, 1982).
As previously discussed, there was a difference between groups in their use of
psychotropic medications. This was expected, as individuals without an Axis I diagnosis should
not be expected to be on psychotropic mediations without reason. The most likely explanation
for the use of psychotropic medications within this control group would be to control behavior
problems, which would have created a less-than-representative control population for this study.
Based on this rationale, the control group is believed to be an accurate representation of
institutionalized adults with ID. The SSD and psychopathology groups did not differ on their use
of psychotropic medications. The commonality of treatment with psychotropic medication
across many Axis I disorders is well documented for both the ID population (Holden et al., 2004;
Lund, 1985; Singh et al., 2005) including guidance for treatment decision-making (Sturmey,
1995) and use in the general population (Lakey et al., 2005)
Pair-wise comparisons on specific items yielded mixed results. Table 4 presented results
of noteworthy post-hoc comparisons. Only two of fifty-two items were able to significantly
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distinguish the SSD group from the psychopathology and control groups. However, five items
were able to successfully distinguish the control group from at least one other group. Grimacing
was the one behavior within the Stereotyped Behaviors subscale that was able to differentiate the
SSD group from the psychopathology and control groups. The second item in which scores were
significantly higher for the SSD group than both comparison groups was being verbally abusive
to others. This item falls within the Aggressive/Destructive Behavior subscale on the BPI.
Verbal aggression has been linked with disorders included within the SSD group in previous
literature (Foley, Kelly, Clarke, McTigue, Gervin, Kamali et al., 2005; Milton, Amin, Singh,
Harrison, Jones, Croudace et al., 2001).
Results of one ANCOVA revealed that overall frequency of behavior problems on the
BPI significantly covaried with frequency of endorsements on the Schizophrenia subscale of the
DASH-II. This result was expected, as behavior problems rarely present as a single problem
behavior (Saloviita, 2002). However, the ANCOVA examining severity of these same scales
found no differences. One potential explanation for these results could be different operational
definitions regarding severity between the two scales. The BPI asks how serious behaviors are
when they occur, whereas the DASH-II orients the severity of behaviors based on their effect on
others (interrupting others, causing harm or damage to property, etc). Furthermore, many of the
behaviors in the Schizophrenia subscale of the BPI are not expected to cause significant troubles
for others. Items including talking to oneself, talking to inanimate objects, hearing voices, or
mood being totally unrelated to what is going on around a person may certainly be odd, but are
not often going to cause significant disruption in the lives of others around them within this
population.
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Although significant differences between the SSD and psychopathology groups were not
always found, many items were able to be differentiated from the control group. These data
suggest Axis I diagnoses in general may significantly contribute to behavioral problems leading
to restrictive placement. The inability to create a target plan to improve behavior specifically
within the SSD population does not keep one from targeting those behaviors identified which are
significant based on psychopathology in general. The effectiveness of behavior checklists within
this population has been well documented (Rojahn, 1984; Rojahn et al., 2001; 2003; Singh et al.,
1991). One can still utilize behavioral instruments to identify these target behaviors which
potentially restrict placement and address them accordingly.
A number of strengths and weaknesses exist in this study. The inclusion of only
participants currently clinically elevated on the Schizophrenia subscale of the DASH-II was a
strength of the study. Another particular strength of this study was the inclusion of participants
from multiple sites, which is uncommon to find in the literature within the ID population.
Participants were screened to be sure that there were signs of active psychosis at the time of
rating in addition to being diagnosed with a SSD. Furthermore, results of correlations between
stereotypy related subscales of both measures suggested accurate and consistent responses to
questions between the two measures.
Sample size was likely the most significant weakness of this study. The power of the
final sample was less than ideal, potentially leading to Type II errors. The original sample
included 22 participants per group. Over one-third of the gathered sample was excluded due to
inclusion criteria to insure participants experiencing forms of active psychosis due to the DASHII Schizophrenia subscale. This does not insure diagnostic accuracy, but does lend support to
correct diagnoses and proper placement within this study. A larger sample size would have been
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preferred, but the stringent inclusion criteria and low prevalence rates of the studied disorders
made this impossible. The trade off of power for quality of the sample seemed appropriate.
However, this did highlight one problem with research in this area. The inherent difficulties of
recruiting a large SSD sample is one of the likely reasons large-scale studies are rare within this
population. Another potential weakness of this study may be the grouping of disorders rather
than studying one specific disorder. However, within the study of these disorders, grouping
these disorders is common (Erkiron et al., in press; Esterberg & Compton, 2005; Lysaker et al.,
2005; Lysaker & Hammersley, in press; Margolese et al., 2006; Matsura et al., 2004; Mizrahi et
al., 2006; Rodríguez-Sánchez et al., 2005; Roofeh et al.; 2006, Sim et al., 2004; Ueland et al,
2004). Regardless, the study of one disorder independent of related disorders would remove a
potential source of variation and improve future studies.
Future research should focus on utilizing larger samples than what is often found in the
literature. The current study, along with many studies in the literature today, may have lacked
the power to adequately identify differences within groups. Larger samples may be able to
identify whether or not behavioral differences exist across varying levels of intellect within the
SSD population. Behavioral checklists such as the BPI could be extended to individuals with
borderline intellectual functioning as well as normal intellectual functioning with SSD.
Furthermore, controlling for specific medications would be beneficial as a means of reducing
error within the study of challenging behavior in the SSD population. In addition, particular
areas of behavior problems not specifically identified with the BPI may also be worthy of study
when considering factors affecting potentially restrictive living situations. A study involving
additional behaviors may be beneficial. One would suspect behaviors such as medication
incompliance (Petrakis, Nich, & Ralevski, 2006), general opposition to authority, and defiance
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may have significant implications regarding one’s ability to maintain more independent living
situations.
In summary, the results of this study showed few specific items of the BPI endorsed
differently between the SSD group and the psychopathology group. However, more significant
differences were found between groups with psychopathology versus controls on BPI items.
Results suggest these behavior problems may be associated with psychopathology rather than
being specific to SSD. Although not enough differences were found between groups to support
the creation of any behavioral profile of the SSD group, results did show good convergent and
divergent validity of expected items between the BPI and DASH-II for the Stereotypic Behavior
subscales of each item.
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